coadministered cagrilintide and semaglutide in adults with overweight or obesity New the August 14, 2025, issue of NEJM: ⁣ ⁣ Cagrilintide–Semaglutide for (REDEFINE 1 phase 3a trial)⁣ ⁣ Cagrilintide– for Overweight Diabetes (REDEFINE 2 phase 3a trial)⁣ ⁣ Updates in Medicine | CagriSema

For the complete reconstitution workflow, see How to Reconstitute Peptides: A Step-by-Step Guide for Researchers

Many individuals find that the most meaningful functional gains occur during extended treatment

In this case, patients were fed highly processed and prepared meals that would be extremely difficult to replicate and maintain in daily life outside of the study

Split dosing can divide daily doses into two smaller injections (1 mg morning + 1 mg evening) for targeted healing and more stable blood levels throughout the day

There is no published human safety dataset for the combination

1 2 "Activation of CaMKII in single dendritic spines during long-term potentiation"